New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Ascendis Pharma

Contributing Author

Recent Articles by Ascendis Pharma

Sep-02	Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 ASND GlobeNewswire
Aug-28	Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference ASND GlobeNewswire
Aug-07	Ascendis Pharma Reports Second Quarter 2025 Financial Results ASND GlobeNewswire
Jul-31	Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 ASND GlobeNewswire
Jul-28	FDA Approves SKYTROFA (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency ASND GlobeNewswire
Jul-14	New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life ASND GlobeNewswire
Jul-07	Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 ASND GlobeNewswire
Jun-09	TransCon hGH Boosted Treatment Benefits of TransCon CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial ASND GlobeNewswire
Jun-02	FDA Accepts TransCon CNP NDA for Priority Review ASND GlobeNewswire
May-13	New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CNP (Navepegritide) ASND GlobeNewswire
May-12	New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism ASND GlobeNewswire
May-05	Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 ASND GlobeNewswire
May-01	Ascendis Pharma Reports First Quarter 2025 Financial Results ASND GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.